YamogeninCAS# 512-06-1 |
- Diosgenin
Catalog No.:BCN6272
CAS No.:512-04-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 512-06-1 | SDF | Download SDF |
| PubChem ID | 441900 | Appearance | White powder |
| Formula | C27H42O3 | M.Wt | 414.63 |
| Type of Compound | Isoprenoids | Storage | Desiccate at -20°C |
| Synonyms | Jamogenin; Neodiosgenin | ||
| Solubility | Soluble in chloroform; insoluble in water | ||
| SMILES | CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)O)C)C)C)OC1 | ||
| Standard InChIKey | WQLVFSAGQJTQCK-CAKNJAFZSA-N | ||
| Standard InChI | InChI=1S/C27H42O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h5,16-17,19-24,28H,6-15H2,1-4H3/t16-,17-,19-,20+,21-,22-,23-,24-,25-,26-,27+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Yamogenin Dilution Calculator
Yamogenin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4118 mL | 12.0589 mL | 24.1179 mL | 48.2358 mL | 60.2947 mL |
| 5 mM | 0.4824 mL | 2.4118 mL | 4.8236 mL | 9.6472 mL | 12.0589 mL |
| 10 mM | 0.2412 mL | 1.2059 mL | 2.4118 mL | 4.8236 mL | 6.0295 mL |
| 50 mM | 0.0482 mL | 0.2412 mL | 0.4824 mL | 0.9647 mL | 1.2059 mL |
| 100 mM | 0.0241 mL | 0.1206 mL | 0.2412 mL | 0.4824 mL | 0.6029 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Diosgenin
Catalog No.:BCN6272
CAS No.:512-04-9
- Withaferin A
Catalog No.:BCC7495
CAS No.:5119-48-2
- Boc-D-Asp(OBzl)-OH
Catalog No.:BCC3371
CAS No.:51186-58-4
- Episyringaresinol
Catalog No.:BCN7023
CAS No.:51152-20-6
- (R)-(-)-Ibuprofen
Catalog No.:BCC4062
CAS No.:51146-57-7
- (S)-(+)-Ibuprofen
Catalog No.:BCC4042
CAS No.:51146-56-6
- (+)-trans-Isolimonene
Catalog No.:BCC9236
CAS No.:5113-87-1
- Cyclic Pifithrin-α hydrobromide
Catalog No.:BCC2407
CAS No.:511296-88-1
- 8-Bromo-cGMP, sodium salt
Catalog No.:BCC6935
CAS No.:51116-01-9
- Gitogenin
Catalog No.:BCN3886
CAS No.:511-96-6
- Plumieride
Catalog No.:BCN5631
CAS No.:511-89-7
- Vitamin D4
Catalog No.:BCC2042
CAS No.:511-28-4
- Raffinose
Catalog No.:BCN8427
CAS No.:512-69-6
- Ascaridole
Catalog No.:BCC8121
CAS No.:512-85-6
- Boc-Arg(Z)-OH
Catalog No.:BCC3068
CAS No.:51219-18-2
- 6,8-Diprenylgenistein
Catalog No.:BCN4805
CAS No.:51225-28-6
- Wighteone
Catalog No.:BCN5632
CAS No.:51225-30-0
- N-Phthaloyl-Phe-OH
Catalog No.:BCC3016
CAS No.:5123-55-7
- Amsacrine
Catalog No.:BCC4309
CAS No.:51264-14-3
- Gallocatechin gallate
Catalog No.:BCN6803
CAS No.:5127-64-0
- 2,6-Dimethyl-3,7-octadiene-2,6-diol
Catalog No.:BCN5633
CAS No.:51276-34-7
- Afzelechin 3-O-xyloside
Catalog No.:BCN7774
CAS No.:512781-45-2
- 5,7-Diacetoxy-3,4',8-trimethoxyflavone
Catalog No.:BCN1432
CAS No.:5128-43-8
- 7,4'-Di-O-methylapigenin
Catalog No.:BCN5634
CAS No.:5128-44-9
Anti-neutrophilic inflammatory steroidal glycosides from Solanum torvum.[Pubmed:23838628]
Phytochemistry. 2013 Nov;95:315-21.
Torvpregnanosides A and B, two pregnane glycosides, and torvoside Q, a 23-keto-spirostanol glycoside, along with twelve known steroidal saponins were isolated from aerial parts of Solanum torvum. Of the latter, four of the 23-hydroxy-spirostanol glycosides, and, a Yamogenin glycoside, were in this plant discovered. All structures were identified from spectroscopic data, and all the compounds were tested for in vitro anti-neutrophilic inflammatory activity. Two compounds showed selective inhibition against elastase release and superoxide anion generation, respectively, by human neutrophils with IC50 values of 5.66 and 3.59 muM, while two others inhibited both inflammatory mediators with IC50 values of 0.66-3.49 muM. Structure-activity relationships are discussed.
Yamogenin in fenugreek inhibits lipid accumulation through the suppression of gene expression in fatty acid synthesis in hepatocytes.[Pubmed:25229863]
Biosci Biotechnol Biochem. 2014;78(7):1231-6.
Yamogenin is a diastereomer of diosgenin, which we have identified as the compound responsible for the anti-hyperlipidemic effect of fenugreek. Here, we examined the effects of Yamogenin on the accumulation of triacylglyceride (TG) in hepatocytes, because Yamogenin is also contained in fenugreek. It was demonstrated that Yamogenin also inhibited TG accumulation in HepG2 hepatocytes and suppressed the mRNA expression of fatty acid synthesis-related genes such as fatty acid synthase and sterol response element-binding protein-1c. Indeed, Yamogenin also antagonized the activation of the liver X receptor (LXR) in luciferase ligand assay similar to diosgenin. However, Yamogenin could not exert such effects in the presence of T0901713, a potent agonist of LXR. These findings indicate that the effects of Yamogenin on TG accumulation would be weaker than those of diosgenin, suggesting that the structural difference between Yamogenin and diosgenin would be important for the inhibition of LXR activation.
[Effect and mechanism of methyl protodioscin in protecting cardiomyocytes against anoxia/reoxygenation injury].[Pubmed:20669680]
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010 Apr;30(4):407-9.
OBJECTIVE: To study the effect and mechanism of methyl protodioscin (MPD), an active ingredients of Yamogenin, in protecting cardiomyocytes (CMC) against anoxia/reoxygenation (A/R) injury. METHODS: Cultured CMCs of neonatal SD rats were randomly divided into three groups, cells in Group A were untreated normal cells, cells in Group B and C were made to injury CMC model by A/R, and only those in Group C were treated with MPD. Levels of ATPase activity and lactate dehydrogenase (LDH) in cell membrane of CMCs were determined. Besides, the mRNA expression of sodium-calcium exchanger (NCX) in MPD treated CMCs was detected. RESULTS: As compared with Group B, the degree of CMC injury was significantly milder and the activities of Na+ -K+ -ATPase and Ca2+ -Mg2+ -ATPase were higher in Group C after cells were treated with MPD in concentration of 10 microg/mL and 50 microg/mL. The mRNA expression of NCX in CMCs was down-regulated after MPD treatment (P < 0.05). CONCLUSION: MPD could maintain the low calcium internal environment in CMCs by way of protecting the membranous function of Na+ -pump and Ca2+ -pump, and influencing the Ca2+ transmembrane transportation in CMCs.
Cytotoxic steroidal saponins from Panicum turgidum Forssk.[Pubmed:28629616]
Steroids. 2017 Sep;125:14-19.
Three new bidesmosidic cholestane-type steroidal glycosides, 16-O-beta-d-glucopyranosyl-cholest-5-en-3beta,16beta-diol-22-one-3-O-alpha-l-rham nopyranosyl-(1-->2)-O-[(beta-d-glucopyranosyl(1-->4)]-O-beta-d-glucopyranoside (1), 16-O-beta-d-glucopyranosylcholest-5-en-3beta,16beta-diol-22-one-3-O-alpha-l-rhamn opyranosyl-(1-->2)-O-beta-d-glucopyranoside (2), and 16-O-beta-d-glucopyranosylcholestan-3beta,16beta-diol-6,22-dione-3-O-alpha-l-rham nopyranosyl-(1-->2)-O-beta-d-glucopyranoside (3) were isolated from a methanolic extract of Panicum turgidum. In addition four known compounds, pennogenin 3beta-O-alpha-l-rhamnopyranosyl-(1-->2)-O-[alpha-l-rhamnopyranosyl-(1-->4)-O-alph a-l-rhamnopyranosyl-(1-->4)]-O-beta-d-glucopyranoside (4), Yamogenin 3beta-O-alpha-l-rhamnopyranosyl-(1-->2)-O-[alpha-l-rhamnopyranosyl-(1-->4)]-O-bet a-d-glucopyranoside (5), Yamogenin 3beta-O-alpha-l-rhamnopyranosyl-(1-->2)-O-[alpha-l-rhamnopyranosyl-(1-->4)-O-alph a-l-rhamnopyranosyl-(1-->4)]-O-beta-d-glucopyranoside (6), and pennogenin 3beta-O-alpha-l-rhamnopyranosyl-(1-->2)-O-[alpha-l-rhamnopyranosyl-(1-->4)]-O-bet a-d-glucopyranoside (7) were also isolated and characterized. Their structures were established using extensive spectroscopic methods including 1D and 2D NMR and HRESIMS. The isolated compounds were screened for cytotoxicity towards a panel of mammalian cell lines and 4-7 were found to be cytotoxic.
